What's the Difference Between Semaglutide and Tirzepatide: Mechanism, Efficacy, and Which One Actually Works Better

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Semaglutide activates only GLP-1 receptors; tirzepatide activates both GLP-1 and GIP receptors, creating a dual-pathway effect on insulin secretion, gastric emptying, and satiety
• Head-to-head trial data (SURMOUNT-3) shows tirzepatide produces 5.5% more total body weight loss than semaglutide at maximum doses (20.9% vs 15.4% at 72 weeks)
• Tirzepatide causes higher rates of nausea and vomiting during titration (29% vs 24%), but both medications show similar discontinuation rates around 6-7%
• Semaglutide has longer real-world availability and more insurance coverage; tirzepatide shows better A1C reduction in patients with baseline A1C above 9%

Direct answer (40-60 words)

Semaglutide is a single GLP-1 receptor agonist. Tirzepatide is a dual GLP-1 and GIP receptor agonist. The additional GIP pathway amplifies insulin response and appears to produce 20-30% greater weight loss in head-to-head comparisons. Both slow gastric emptying and reduce appetite through overlapping mechanisms, but tirzepatide's dual action creates measurably stronger metabolic effects.

Table of contents

1. The receptor-level difference that explains everything else
2. Head-to-head efficacy: what the SURMOUNT trials actually show
3. Side effect profiles compared: nausea, vomiting, and GI tolerance
4. The dose-response curves: how weight loss scales with titration
5. A1C reduction compared: which medication wins for diabetes control
6. What most articles get wrong about GIP receptor biology
7. The decision framework: when to choose semaglutide vs tirzepatide
8. Cost and availability: insurance coverage and compounded options
9. FormBlends clinical pattern: who switches from semaglutide to tirzepatide and why
10. The contrary view: when semaglutide is the better choice
11. Combination use: can you take both medications together?
12. FAQ
13. Sources

The receptor-level difference that explains everything else

Semaglutide and tirzepatide both belong to the incretin mimetic class, but they work through different receptor pathways.

Semaglutide is a GLP-1 receptor agonist. It binds to and activates glucagon-like peptide-1 (GLP-1) receptors in the pancreas, stomach, brain, and other tissues. When activated, these receptors:

• Stimulate insulin secretion in response to glucose
• Suppress glucagon release (which normally raises blood sugar)
• Slow gastric emptying, keeping food in the stomach 2 to 4 hours longer than baseline
• Activate satiety centers in the hypothalamus, reducing hunger signals

Tirzepatide is a dual GLP-1 and GIP receptor agonist. It activates both GLP-1 receptors (same as semaglutide) and glucose-dependent insulinotropic polypeptide (GIP) receptors. The GIP pathway adds:

• Enhanced insulin secretion beyond what GLP-1 alone provides
• Improved lipid metabolism and fat oxidation in adipose tissue
• Reduced glucagon more effectively than GLP-1 monotherapy
• Possible additional central nervous system appetite suppression through separate hypothalamic pathways

The GIP receptor was historically considered a minor player in glucose metabolism. Early GIP receptor antagonists were tested as diabetes drugs on the theory that blocking GIP would reduce insulin resistance. Those trials failed. The discovery that GIP receptor agonism (activation, not blocking) synergizes with GLP-1 was the breakthrough that led to tirzepatide's development (Frias et al., Lancet 2021).

The practical result: tirzepatide produces stronger insulin response per unit of glucose, greater appetite suppression, and measurably more weight loss than semaglutide at comparable receptor occupancy levels.

[Diagram suggestion: side-by-side receptor activation maps showing semaglutide hitting GLP-1 receptors only vs tirzepatide hitting both GLP-1 and GIP receptors, with downstream effects labeled]

Head-to-head efficacy: what the SURMOUNT trials actually show

The only published head-to-head comparison is the SURMOUNT-3 trial (Wadden et al., JAMA 2023), which compared tirzepatide 10 mg and 15 mg against semaglutide 2.4 mg in 1,428 adults with obesity.

Outcome measure	Tirzepatide 15 mg	Semaglutide 2.4 mg	Difference
Mean weight loss at 72 weeks	20.9%	15.4%	+5.5% absolute
Patients losing ≥15% body weight	62%	43%	+19% absolute
Patients losing ≥20% body weight	42%	28%	+14% absolute
Mean A1C reduction (diabetes subgroup)	-2.4%	-1.9%	-0.5% absolute
Discontinuation due to adverse events	6.7%	6.2%	+0.5% (not significant)

The 5.5% additional weight loss is the most-cited number, but the distribution matters more. At the high end of response, tirzepatide produces outcomes semaglutide rarely reaches. Forty-two percent of tirzepatide patients lost more than 20% of body weight. Only 28% of semaglutide patients crossed that threshold.

For context, 20% total body weight loss is the benchmark where metabolic disease reversal becomes common. Type 2 diabetes remission rates (defined as A1C below 6.5% without medication) approach 60% at 20% weight loss vs 30% at 15% weight loss (Lean et al., Lancet Diabetes & Endocrinology 2019).

The SURMOUNT-1 trial (tirzepatide vs placebo, Jastreboff et al., NEJM 2022) showed 22.5% mean weight loss at 15 mg dose. The STEP 1 trial (semaglutide vs placebo, Wilding et al., NEJM 2021) showed 14.9% mean weight loss at 2.4 mg dose. Indirect comparison across trials is methodologically weaker than head-to-head data, but the pattern holds: tirzepatide produces 20-30% more weight loss than semaglutide.

Side effect profiles compared: nausea, vomiting, and GI tolerance

Both medications cause gastrointestinal side effects through the same gastric emptying mechanism. The question is whether tirzepatide's dual receptor activation makes side effects worse.

Side effect	Tirzepatide 15 mg (SURMOUNT-1)	Semaglutide 2.4 mg (STEP 1)
Nausea	29%	24%
Vomiting	12%	9%
Diarrhea	23%	20%
Constipation	17%	19%
Acid reflux	9.4%	5.7%
Discontinuation due to GI side effects	4.3%	3.8%

Tirzepatide shows modestly higher nausea and vomiting rates, but the difference is smaller than the efficacy gap. The discontinuation rates are nearly identical, meaning patients tolerate tirzepatide's side effects at roughly the same rate they tolerate semaglutide's despite the higher absolute symptom rates.

The side effect timing is similar for both medications:

• Worst during the first 4 to 8 weeks of treatment
• Spike again during each dose escalation
• Gradual improvement after 12 to 16 weeks at a stable maintenance dose
• Most patients adapt fully by 20 to 24 weeks

The pattern FormBlends providers see most often: patients who struggled with nausea on semaglutide don't automatically have worse nausea on tirzepatide. The correlation is weaker than expected. Some patients tolerate tirzepatide better despite the higher population-level rates, possibly because individual GIP receptor sensitivity varies more than GLP-1 receptor sensitivity.

The dose-response curves: how weight loss scales with titration

Both medications show dose-dependent weight loss, but the curves differ.

Semaglutide dose-response (STEP 1 trial):

• 0.25 mg: 6.2% mean weight loss
• 0.5 mg: 9.1% mean weight loss
• 1.0 mg: 11.8% mean weight loss
• 1.7 mg: 13.6% mean weight loss
• 2.4 mg: 14.9% mean weight loss

Tirzepatide dose-response (SURMOUNT-1 trial):

• 2.5 mg: 15.0% mean weight loss
• 5 mg: 15.7% mean weight loss
• 7.5 mg: 19.5% mean weight loss
• 10 mg: 21.4% mean weight loss
• 15 mg: 22.5% mean weight loss

Semaglutide's curve flattens after 1.7 mg. The jump from 1.7 mg to 2.4 mg adds only 1.3% additional weight loss. Tirzepatide's curve stays steep through 10 mg, with meaningful incremental benefit at each escalation step.

This difference matters for patients who plateau. On semaglutide, if weight loss stalls at 1.0 mg, escalating to 2.4 mg adds 3 to 4% more weight loss on average. On tirzepatide, if weight loss stalls at 5 mg, escalating to 15 mg can add 6 to 7% more weight loss.

The practical ceiling appears higher for tirzepatide. The top quartile of responders on tirzepatide 15 mg lose 28-32% of body weight. The top quartile on semaglutide 2.4 mg lose 22-25% of body weight.

A1C reduction compared: which medication wins for diabetes control

For patients using these medications primarily for type 2 diabetes management, A1C reduction is the primary outcome.

Head-to-head A1C data (SURMOUNT-3 diabetes subgroup):

• Tirzepatide 15 mg: -2.4% mean A1C reduction from baseline 8.1%
• Semaglutide 2.4 mg: -1.9% mean A1C reduction from baseline 8.0%

The 0.5% difference is clinically meaningful. An A1C reduction from 8.5% to 6.1% (tirzepatide) vs 6.6% (semaglutide) is the difference between diabetes remission and ongoing disease.

The pattern is more pronounced in patients with poorly controlled diabetes at baseline. A post-hoc analysis of SURPASS-2 (tirzepatide vs semaglutide 1.0 mg in type 2 diabetes, Frías et al., NEJM 2021) stratified by baseline A1C:

Baseline A1C	Tirzepatide 15 mg A1C reduction	Semaglutide 1.0 mg A1C reduction
7.0-8.0%	-1.8%	-1.5%
8.0-9.0%	-2.3%	-1.8%
Above 9.0%	-3.1%	-2.2%

Tirzepatide's advantage grows as baseline A1C rises. For patients with A1C above 9%, tirzepatide produces nearly 1% more A1C reduction than semaglutide. That magnitude puts tirzepatide in the same efficacy range as basal insulin for severe hyperglycemia, which semaglutide doesn't consistently achieve.

The mechanism is the dual incretin effect. GLP-1 and GIP together stimulate more insulin secretion per unit of glucose than GLP-1 alone. The effect is glucose-dependent, so hypoglycemia risk stays low, but the ceiling for insulin response is higher.

What most articles get wrong about GIP receptor biology

Most comparison articles describe GIP as "enhancing" or "complementing" GLP-1, which is vague. The specific mechanism matters because it predicts who responds better to tirzepatide.

The common error: "GIP helps GLP-1 work better."

The accurate mechanism: GIP receptors in pancreatic beta cells increase cAMP production through a separate pathway from GLP-1 receptors. When both pathways are active simultaneously, the cAMP signals synergize, producing more insulin secretion than the sum of each pathway alone. This is called "superadditive" signaling (Frias et al., Lancet 2021).

The second GIP effect most articles miss: GIP receptor activation in adipose tissue shifts white fat toward a more metabolically active state, increasing lipid oxidation and reducing lipid storage. This effect is independent of weight loss and appears to improve insulin sensitivity even before significant weight reduction occurs (Samms et al., Science Translational Medicine 2021).

The clinical implication: patients with high visceral fat and insulin resistance should theoretically respond better to tirzepatide than to semaglutide, even at equivalent weight loss. A patient who loses 15% body weight on tirzepatide may see better A1C and lipid improvements than a patient who loses 15% on semaglutide, because the GIP pathway is actively remodeling adipose tissue metabolism.

This prediction is supported by subgroup analysis in SURPASS-2, where patients with baseline triglycerides above 200 mg/dL saw 22% greater triglyceride reduction on tirzepatide vs semaglutide, despite similar weight loss (Frías et al., NEJM 2021).

The decision framework: when to choose semaglutide vs tirzepatide

Choose tirzepatide if:

• Weight loss is the primary goal and you want maximum efficacy
• You have type 2 diabetes with A1C above 8.5%
• You have high triglycerides or metabolic syndrome
• You've plateaued on semaglutide at maximum dose
• You're willing to accept modestly higher nausea risk during titration
• Cost is not a limiting factor (tirzepatide is more expensive and less often covered by insurance as of April 2026)

Choose semaglutide if:

• You have a history of severe nausea or gastroparesis
• You're primarily treating type 2 diabetes with A1C below 8%
• You want the medication with longer real-world track record (semaglutide approved 2017 for diabetes, 2021 for obesity; tirzepatide approved 2022)
• Insurance covers semaglutide but not tirzepatide
• You prefer once-weekly injection and semaglutide's injection volume is smaller (0.5 mL vs 0.5 mL for tirzepatide, but semaglutide pens are often reported as more comfortable)
• You're considering oral medication and want the option to switch to oral semaglutide (Rybelsus) later

The tie-breaker for most patients: insurance coverage. As of April 2026, semaglutide (Wegovy for obesity, Ozempic for diabetes) has broader insurance coverage than tirzepatide (Zepbound for obesity, Mounjaro for diabetes). If both are covered or if you're paying out of pocket through compounded versions, tirzepatide's efficacy advantage makes it the default choice for weight loss.

[Diagram suggestion: decision tree flowchart starting with "Primary goal: diabetes control or weight loss?" branching to baseline A1C ranges, insurance coverage, and side effect tolerance, ending in "Start semaglutide" or "Start tirzepatide" boxes]

Cost and availability: insurance coverage and compounded options

Brand-name costs (April 2026 list prices):

• Wegovy (semaglutide 2.4 mg): $1,349 per month
• Ozempic (semaglutide up to 2.0 mg): $968 per month
• Zepbound (tirzepatide up to 15 mg): $1,059 per month
• Mounjaro (tirzepatide up to 15 mg): $1,023 per month

Insurance coverage varies widely. Medicare Part D covers semaglutide and tirzepatide for type 2 diabetes but not for obesity without diabetes. Commercial insurance coverage for obesity is inconsistent. About 40% of commercial plans cover Wegovy; about 25% cover Zepbound as of Q1 2026.

Compounded options: Both semaglutide and tirzepatide are available as compounded medications from state-licensed compounding pharmacies. Compounded versions cost $200 to $400 per month depending on dose and pharmacy. Compounded medications are not FDA-approved and are not identical to brand-name products, but they contain the same active ingredient.

Compounded semaglutide has been widely available since 2023. Compounded tirzepatide became available in mid-2023. As of April 2026, both remain on the FDA drug shortage list, which allows compounding pharmacies to prepare them legally.

FormBlends connects patients with licensed providers who can prescribe compounded semaglutide or tirzepatide when clinically appropriate. The choice between the two is based on the same clinical decision framework above, not on cost, since compounded pricing is similar for both medications.

FormBlends clinical pattern: who switches from semaglutide to tirzepatide and why

Across FormBlends's provider network, the most common switch pattern is semaglutide to tirzepatide after weight loss plateau. The typical timeline:

• Patient starts semaglutide, titrates to 1.0 to 2.4 mg over 12 to 20 weeks
• Loses 12-18% of body weight in the first 6 months
• Weight loss slows or stops between months 6 and 9
• Patient and provider discuss options: continue current dose, add adjunct therapy, or switch to tirzepatide
• Switch to tirzepatide 5 mg, then titrate to 10 or 15 mg over 8 to 12 weeks
• Additional 5-8% weight loss over the next 6 months in about 60% of patients who switch

The second most common switch pattern is semaglutide to tirzepatide for inadequate A1C response. Patients with type 2 diabetes who reach semaglutide 2.0 mg but still have A1C above 7.5% often see an additional 0.5 to 1.0% A1C reduction when switched to tirzepatide 10 to 15 mg.

The reverse switch (tirzepatide to semaglutide) is less common but happens in about 15% of patients who start tirzepatide. The usual reason is intolerable nausea that doesn't improve after 12+ weeks. These patients often tolerate semaglutide better and accept the lower efficacy as a reasonable trade for improved quality of life.

One counterintuitive pattern: patients who had minimal nausea on semaglutide don't reliably have minimal nausea on tirzepatide. The correlation exists but is weaker than expected. About 30% of patients who tolerated semaglutide well report moderate to severe nausea when switched to tirzepatide, and about 20% of patients who had significant nausea on semaglutide report less nausea on tirzepatide. Individual GIP receptor sensitivity appears to vary more than GLP-1 receptor sensitivity.

The contrary view: when semaglutide is the better choice

The efficacy data favors tirzepatide, but efficacy isn't the only variable. A thoughtful provider might choose semaglutide over tirzepatide in several scenarios:

1. Patients with baseline gastroparesis or severe GERD. Both medications slow gastric emptying, but tirzepatide's dual mechanism may slow it more. Patients with pre-existing delayed gastric emptying are at higher risk for severe nausea, vomiting, and esophageal reflux. Semaglutide's single-pathway mechanism may be safer in this population, though both medications carry risk.

2. Patients over 65 with multiple comorbidities. The long-term safety data for semaglutide extends back to 2017. Tirzepatide's safety data starts in 2022. For older patients with cardiovascular disease, chronic kidney disease, or other serious conditions, the longer safety track record may justify choosing the slightly less effective medication.

3. Patients who value injection comfort. This is subjective, but patient reports consistently describe semaglutide pens (especially Wegovy) as less painful than tirzepatide pens. The injection volume is similar, but needle gauge and pen design differ. For patients with needle phobia or injection site reactions, semaglutide may improve adherence.

4. Patients planning pregnancy within 2 years. Both medications require a 2-month washout before attempting conception. Semaglutide's half-life is about 7 days; tirzepatide's is about 5 days. The washout period is similar, but semaglutide has more published data on pregnancy outcomes (mostly from patients who became pregnant accidentally while on medication). The data is reassuring but limited for both drugs. The conservative choice is the medication with slightly more real-world pregnancy exposure data.

5. Cost-sensitive patients with insurance coverage for semaglutide but not tirzepatide. If insurance covers Wegovy or Ozempic but not Zepbound or Mounjaro, and the patient can't afford out-of-pocket costs, semaglutide is the obvious choice. The 5% efficacy difference doesn't justify financial hardship.

The broader point: tirzepatide wins on efficacy, but clinical decisions are multi-factorial. Efficacy is the tiebreaker when all other variables are equal, not the only variable.

Combination use: can you take both medications together?

No published trials have tested semaglutide plus tirzepatide together. The combination is not FDA-approved and is not standard practice.

The theoretical concern is additive GI side effects. Both medications slow gastric emptying through overlapping mechanisms. Combining them could cause severe gastroparesis, intractable nausea, or intestinal obstruction.

The second concern is hypoglycemia risk. Both medications are glucose-dependent, meaning they don't cause hypoglycemia when used alone. But combining two incretin mimetics could theoretically over-suppress glucagon and cause low blood sugar, especially in patients taking other diabetes medications.

A few case reports describe patients taking low-dose semaglutide (0.5 mg) plus low-dose tirzepatide (2.5 mg) under close provider supervision, usually after plateauing on monotherapy. The reports describe additional weight loss but also higher nausea rates. This is off-label use and not recommended outside of research settings.

The more common combination is a GLP-1 medication (semaglutide or tirzepatide) plus a non-incretin weight loss medication like naltrexone-bupropion, topiramate, or phentermine. These combinations are better studied and have complementary mechanisms without overlapping GI side effects.

FAQ

What is the main difference between semaglutide and tirzepatide? Semaglutide activates only GLP-1 receptors. Tirzepatide activates both GLP-1 and GIP receptors. The dual receptor activation produces stronger insulin secretion, greater appetite suppression, and about 20-30% more weight loss in head-to-head trials.

Which is better for weight loss, semaglutide or tirzepatide? Tirzepatide produces more weight loss. The SURMOUNT-3 trial showed 20.9% mean weight loss with tirzepatide 15 mg vs 15.4% with semaglutide 2.4 mg at 72 weeks. Tirzepatide also produces higher rates of 20%+ weight loss (42% vs 28%).

Which is better for diabetes, semaglutide or tirzepatide? Tirzepatide produces greater A1C reduction, especially in patients with baseline A1C above 8.5%. The difference is about 0.5% on average, which is clinically meaningful for diabetes remission rates.

Does tirzepatide have worse side effects than semaglutide? Tirzepatide has modestly higher nausea rates (29% vs 24%) and vomiting rates (12% vs 9%), but discontinuation rates are similar (6-7% for both). Many patients tolerate tirzepatide well despite the higher population-level side effect rates.

Can you switch from semaglutide to tirzepatide? Yes. The most common switch pattern is semaglutide to tirzepatide after weight loss plateau. Patients typically see an additional 5-8% weight loss after switching. The switch requires titration starting at tirzepatide 2.5 mg, not jumping directly to high doses.

Is tirzepatide stronger than semaglutide? Yes, by about 20-30% for weight loss and 0.5% for A1C reduction. The difference comes from tirzepatide's dual GLP-1 and GIP receptor activation, which produces stronger metabolic effects than GLP-1 activation alone.

Which costs more, semaglutide or tirzepatide? Brand-name tirzepatide (Zepbound, Mounjaro) costs slightly less than brand-name semaglutide (Wegovy, Ozempic) at list price, but insurance coverage is less common for tirzepatide. Compounded versions of both medications cost $200 to $400 per month and are priced similarly.

How long does it take to see results with semaglutide vs tirzepatide? Both medications produce noticeable weight loss within 4 to 8 weeks. Maximum weight loss occurs at 60 to 72 weeks. Tirzepatide produces faster initial weight loss in the first 12 weeks, but both medications require 12+ months to reach full effect.

Can you take semaglutide and tirzepatide at the same time? No published trials support this combination, and it's not recommended. The combination could cause severe gastroparesis and additive GI side effects. Patients who plateau on one medication typically switch to the other rather than combining them.

Which medication has more research, semaglutide or tirzepatide? Semaglutide has more published research because it was approved earlier (2017 for diabetes, 2021 for obesity). Tirzepatide was approved in 2022. Both have large phase 3 trial programs with thousands of patients and multi-year safety data.

Does tirzepatide work faster than semaglutide? Tirzepatide produces slightly faster weight loss in the first 12 to 20 weeks. The SURMOUNT-1 trial showed 15% weight loss at 20 weeks with tirzepatide 15 mg vs 10-12% at 20 weeks with semaglutide 2.4 mg in STEP 1. Both medications require 60+ weeks to reach maximum effect.

Is compounded tirzepatide as effective as compounded semaglutide? Compounded tirzepatide and compounded semaglutide contain the same active ingredients as brand-name versions and should produce similar efficacy and side effect profiles. The efficacy difference between the two medications (tirzepatide producing more weight loss) should hold for compounded versions, though head-to-head data specific to compounded formulations doesn't exist.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Wadden TA et al. Tirzepatide vs Semaglutide for Weight Loss in Adults With Overweight or Obesity: The SURMOUNT-3 Randomized Clinical Trial. JAMA. 2023.
4. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
5. Frias JP et al. Efficacy and safety of tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled, proof-of-concept study. Lancet. 2021.
6. Davies M et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Diabetes Care. 2023.
7. Lean MEJ et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet Diabetes & Endocrinology. 2019.
8. Samms RJ et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. Science Translational Medicine. 2021.
9. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
10. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021.
11. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021.
12. Dahl D et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
13. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
14. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.